Tuesday, May 28, 2013

Crohn's Disease & Ulcerative Colitis at NevBio - Thurs, April 25, 2013

Thursday, April 25th, 12 Noon
Glenn Diamond, Red Green Biotechnology
 McCormick & Schmicks
11:30 Check-in, 12 pm lunch & talk.
$30. (students & researchers free)

"Crohn's Disease & Ulcerative Colitis"
Red Green Biotechnology launch against inflammatory bowel disease epidemic. Innovate Nevada's first parade entrepreneur.
Glenn Diamond is the Founder of Neuropeptide Dynamics and David Pharmaceuticals. He is a polymath featured in Fortune (see article on left) for smart drug development work. One of the last disciples of Bob Swanson immortal founder of Genentech and the world's biotechnology industry.

Over 700,000 Americans have Crohn's Disease. It generally strikes individuals between 15 and 35. Crohn's disease belongs to a group of conditions known as Inflammatory Bowel Diseases (IBD). Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract.
Crohn's most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus.

There is no known cure.

Who is Glenn Diamond?
From Fortune Magazine:
"Perhaps the most remarkable member of the damn-the-torpedoes set is Glenn "Buddy" Diamond, an entrepreneur who set out six years ago to mitigate his son's Down syndrome. That congenital disorder causes not only retardation but also progressive brain damage much like that of Alzheimer's. Starting with zero funding and no drug industry experience, Diamond managed to light a fire under the development of both the Russian and the Novartis drugs, enlist some of biotech's leading lights to back his cause, and inspire the formation of David Pharmaceuticals--the startup is named after his 9-year-old son.

Known to associates as a brilliant, uncompromising polymath, Diamond was a Minneapolis consultant on business turnarounds when David was born. He soon became a self-taught expert on Down syndrome."  See rest of the story here. (Glenn's story starts on the 22nd paragraph.)


JR said...

How can I get in touch with Glenn Diamond's company Neuropeptide Dynamics? Has there been any news on his MCI pharmacological research?

Chuck Bush said...
This comment has been removed by the author.